Assessing Response and Loss of Response to Biological Therapies in IBD

@article{Yanai2011AssessingRA,
  title={Assessing Response and Loss of Response to Biological Therapies in IBD},
  author={H. Yanai and S. Hanauer},
  journal={The American Journal of Gastroenterology},
  year={2011},
  volume={106},
  pages={685-698}
}
  • H. Yanai, S. Hanauer
  • Published 2011
  • Medicine
  • The American Journal of Gastroenterology
  • OBJECTIVES:The advent of biological therapies for inflammatory bowel disease (IBD) began in 1998 with the approval of infliximab for the treatment of refractory (to conventional agents) Crohn’s disease (CD). Since then, the indications for anti-tumor necrosis factor-α (anti-TNFα) therapy have increased to include induction and maintenance of clinical responses and remissions for luminal and fistulizing CD, the treatment of children with CD, and the treatment of adults with ulcerative colitis… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 139 REFERENCES
    Infliximab for induction and maintenance therapy for ulcerative colitis.
    • 2,162
    • PDF